The Remedy Room — Congressional Record
Congressional Voices
The case being made on the floor. Five members of Congress — three Republicans, two Democrats — arriving at the same structural diagnosis from opposite ends of the political spectrum. This is not partisan. It is documented.
The Cross-Spectrum Convergence
A Republican urologic surgeon says prior authorization is the practice of medicine and insurers should pay malpractice insurance. A second Republican urologic surgeon says he needed eight attempts to get his own prescription and calls for breaking up the industry entirely. A conservative senator co-authors the breakup bill with a progressive Democrat. That Democrat gets the CVS CEO on record defending a structure the FTC documented as harmful. The same progressive Democrat's colleague calls for a Glass-Steagall for healthcare.
None of these members coordinated their statements. They arrived here from their own clinical experience, their own constituents, and their own reading of the evidence. That is the signal.
Members
- R Rep. Neal Dunn, MD (R-FL) — Prior Authorization is the Practice of Medicine
- R Rep. Greg Murphy, MD (R-NC) — Eight Attempts & Break Them Up
- R Sen. Josh Hawley (R-MO) — S.3822 Co-Author
- D Sen. Elizabeth Warren (D-MA) — S.3829 Lead Author & S.3822 Co-Author
- D Rep. Alexandria Ocasio-Cortez (D-NY) — CVS on the Record
Rep. Neal Dunn, MD (R-FL)
At a House hearing on healthcare affordability, Rep. Neal Dunn — a urologic surgeon serving in Congress — stated directly that prior authorization constitutes the practice of medicine and that insurers should be held to the same medical liability standard as physicians.
Rep. Dunn was responding to testimony from Dr. David Aizuss, MD, chair of the American Medical Association board of trustees, who described his ophthalmology practice's administrative burden — including two full-time staff hired solely to manage prior authorization requests.
"Prior authorization, whether on the part of an insurance company or whatever, is the practice of medicine. And I would invite them into the medical liability arena. You and I have to pay med-mal insurance, so should they."
— Rep. Neal Dunn, MD (R-FL), urologic surgeon, House hearing on healthcare affordability
Rep. Dunn has not reviewed or endorsed the Clinical Integrity Amendment specifically. This statement represents independent convergence — a Republican physician-congressman arriving at the same accountability mechanism from his own clinical and legislative experience. The argument is arriving from multiple directions simultaneously.
Why this matters for the Clinical Integrity Amendment:
The Amendment's § 5 — Physician Accountability — is built on exactly this premise. If a licensed physician certifies a denial under penalty of perjury and the IRE immediately overturns it, that physician made a false medical determination. Rep. Dunn's statement from the floor — that prior authorization is the practice of medicine — is the legal foundation that makes § 5 coherent. You cannot claim liability immunity for a decision that is, by the admission of a physician-congressman, the practice of medicine.
Rep. Greg Murphy, MD (R-NC)
Rep. Greg Murphy — a urologic surgeon and Republican member of Congress — publicly disclosed at a House hearing on the insurance industry that it took him eight attempts through CVS pharmacy benefit management to obtain his own medication. He stated explicitly that he did not use his congressional position to shortcut the process. He followed standard procedure.
Then he told the insurance executives in the room that vertical integration has destroyed competition in healthcare and that they need to be broken up — invoking Mark Cuban's cost-plus pharmacy model as the market-correction alternative. The Zeteo clip received 77,000 likes and 24,000 shares.
"If I had my way, I'd turn all of you guys into dust. We'd start back from scratch. The vertical integration has destroyed competition in this country... what needs to happen is that you guys need to be broken up."
"It took me eight times through CVS to get that medication. I'm a physician and member of Congress. I didn't pull any strings. I did what I was supposed to do. Imagine the average person in the country."
— Rep. Greg Murphy, MD (R-NC), urologic surgeon, House hearing on insurance industry, January 22, 2026
Rep. Murphy has not reviewed or endorsed the Clinical Integrity Amendment or S.3822 specifically. This statement represents independent convergence — a Republican physician-congressman arriving at the structural breakup conclusion from his own clinical experience inside the system he is calling to dismantle.
The Gideon parallel
In Gideon v. Wainwright, the Supreme Court ruled that a structurally disadvantaged proceeding cannot produce a just outcome. Rep. Murphy's testimony proves the same dynamic in healthcare: if a physician-congressman doing everything correctly still requires eight attempts, the appeals process is not neutral — it is an exhaustion engine. The average patient navigates it alone.
Why this matters for S.3822 — Break Up Big Medicine:
Rep. Murphy's direct naming of vertical integration — insurer owning PBM owning pharmacy owning home health — as the mechanism that destroyed competition is the floor-level validation of S.3822's structural premise. He and Rep. Dunn represent two Republican physician-congressmen arriving independently at the same conclusion: the system cannot be reformed from within. It must be structurally separated. S.3822 is the legislative instrument that does exactly that.
Sen. Josh Hawley (R-MO)
Sen. Josh Hawley is the Republican co-author of S.3822, the Break Up Big Medicine Act — introduced February 10, 2026 alongside Sen. Elizabeth Warren (D-MA). Hawley has been one of the most vocal Senate voices on healthcare vertical integration, naming the mechanism directly: insurers acquiring PBMs, pharmacies, physician practices, and hospitals to eliminate competition and extract profit at every point in the care chain.
The Warren-Hawley pairing is one of the most unusual bipartisan alliances in recent Senate history — a progressive Democrat and a conservative Republican arriving at identical structural conclusions from opposite ends of the political spectrum. That convergence is the signal that this is not ideology. It is math.
"Health insurance companies are buying up PBMs, pharmacies, doctors' practices, and — in some cases — even hospitals. They're killing competition and making healthcare unaffordable. It's time to put patients first."
— Sen. Josh Hawley (R-MO), co-author S.3822, Break Up Big Medicine Act
The Warren-Hawley signal
When a progressive Democrat and a conservative Republican co-author the same structural reform bill, it means the problem has escaped partisan framing. S.3822 is not a left bill or a right bill. It is a response to a documented market failure that is costing patients their health and taxpayers their money — regardless of who they voted for.
What S.3822 does — in Hawley's own terms:
The Break Up Big Medicine Act prohibits parent companies from simultaneously owning insurers or PBMs alongside medical providers or pharmacies. It mandates divestiture within one year of enactment, with automatic profit disgorgement penalties for non-compliance. It empowers the FTC, DOJ, state attorneys general, and private citizens to bring civil actions — including treble damages — against companies that maintain or recreate prohibited ownership structures. Sen. Hawley is not proposing regulation of the existing system. He is proposing its structural demolition.
Sen. Elizabeth Warren (D-MA)
Sen. Elizabeth Warren is the lead author of S.3829, the Corporate Crimes Against Health Care Act of 2026, introduced February 11, 2026, alongside Senators Markey, Blumenthal, Welch, and Merkley, with House co-lead Rep. Maggie Goodlander (D-NH). She is also co-author of S.3822, the Break Up Big Medicine Act, with Sen. Hawley — making her the singular legislative architect connecting both the structural reform and accountability tracks simultaneously.
S.3829 was introduced in direct response to the bankruptcies of Steward Health Care and Genesis Health — two cases where private equity extraction caused institutional collapse that put patients and communities at catastrophic risk. Warren's framework criminalizes the executive conduct that causes patient harm, empowers state AGs to claw back a decade of compensation, and creates civil penalties of up to five times the clawback amount.
"Private equity companies routinely saddle companies they acquire with massive debt, sell off valuable assets, and extract exorbitant dividends and fees — regardless of how their investments perform. When private equity gets hold of health care systems, it is literally a matter of life and death."
— Sen. Elizabeth Warren (D-MA), S.3829 introduction, February 11, 2026
The Section 7 distinction
S.3829's Section 7 investigative authority is what separates it from S.3822. Where S.3822 restructures ownership, S.3829 empowers government investigators to subpoena records, audit claim histories, and build the evidentiary record that individual patients could never construct alone. The evidence of wrongful denial lives inside the insurer. Section 7 opens the door.
Rep. Murphy as the exemplar
Rep. Greg Murphy, MD (R-NC) — a Republican physician-congressman — required eight attempts through CVS/PBM prior authorization to obtain his own medication. He did not use his position to shortcut the process. This is exactly the wrongful denial pattern S.3829's Section 7 investigative authority is designed to audit: documented patient harm caused by insurer conduct that is currently invisible to regulators because the evidence lives inside the company.
See Rep. Murphy's full record on this page ↑The dual-bill architecture
Warren is simultaneously pursuing structural separation (S.3822 with Hawley) and executive accountability (S.3829). These are not redundant — they address different failure modes. S.3822 removes the conflict of interest that motivates wrongful denial. S.3829 punishes the executives who executed it. Both are necessary. Neither alone closes the loop.
Why S.3829 is getting less attention than S.3822 — and why that matters:
S.3822 has the Warren-Hawley bipartisan signal driving media coverage. S.3829 is a Democratic-only bill targeting private equity, which frames it as partisan even though its accountability mechanisms address harms that cross party lines. Rep. Murphy's eight-attempt prior authorization experience is the argument that S.3829 is not a partisan bill — it is a response to a documented system failure that defeated a Republican physician-congressman doing everything right. The investigation S.3829 authorizes is the investigation that would surface what happened to him, and to patients like Michael Kissling, from the inside.
Rep. Alexandria Ocasio-Cortez (D-NY)
At the January 22, 2026 House Health Subcommittee hearing — the same hearing where Rep. Murphy disclosed his eight-attempt prior authorization experience — Rep. Ocasio-Cortez put CVS Health CEO David Joyner on the record about vertical integration. In rapid succession, she confirmed on the record that CVS Health simultaneously owns Aetna (insurance), CVS Pharmacies, and CVS Caremark — a pharmacy benefit manager processing nearly 30% of all U.S. prescriptions annually.
She then named what the FTC had documented: that healthcare conglomerates structured this way charge more — citing thousand-percent markups on cancer and HIV medications — while former CVS CEO Karen Lynch had acknowledged internally that their "captive strategy" would "show up on their financial results," without any corresponding improvement in patient costs or health outcomes. AOC's framing made it explicit: when one corporation owns every side of a healthcare transaction, the patient is not the customer. They are the product.
"Whether you're a blue blooded capitalist or a card carrying democratic socialist, I think corporate monopolies are a problem. And this vertical integration is destroying people's ability to access care."
— Rep. Alexandria Ocasio-Cortez (D-NY), House Health Subcommittee Hearing, January 22, 2026
[On CVS's "captive strategy" benefiting patients] "Yeah. I think it works very well for CVS."
— Rep. Alexandria Ocasio-Cortez (D-NY), in response to CEO David Joyner's claim the model "works really well for the consumer"
Rep. Ocasio-Cortez has not reviewed or endorsed S.3822 specifically. This statement represents independent convergence — a progressive Democrat arriving at the same structural monopoly diagnosis as Sen. Warren, Sen. Hawley, and Rep. Murphy, from her own questioning of CVS's CEO under oath. She called explicitly for a "Glass-Steagall for Health Care" — the same structural separation S.3822 codifies.
The "Kate" example
To illustrate the closed-loop capture, AOC described a fictional patient named Kate — holding an Aetna plan, filling prescriptions at CVS Pharmacy, connected to an Oak Street Health clinic. Every touchpoint in Kate's care funnels revenue to the same parent company. Kate never consented to that arrangement. She just got sick. The fiction makes the structure visible in a way a regulatory filing cannot.
The Jan 22 convergence
The January 22, 2026 hearing produced two of the most widely shared congressional moments on this issue simultaneously: Rep. Murphy's eight-attempt prior authorization disclosure and AOC's CVS vertical integration exchange. Both went viral. Both arrived at the same structural conclusion from opposite ends of the political spectrum — on the same day, in the same building. The argument has escaped partisan framing.
Why this matters for S.3822 — Break Up Big Medicine:
AOC's exchange did something the bill text alone cannot do: it put a CVS CEO on record, under questioning, acknowledging the ownership structure while defending it as a consumer benefit — a defense that the FTC's own findings on medication markups directly contradict. Her call for a "Glass-Steagall for Health Care" is precisely the structural logic S.3822 enacts. When a progressive Democrat, a conservative Republican (Hawley), and two physician-congressmen (Murphy, Dunn) are all naming the same mechanism in the same session of Congress, the structural case has achieved rare cross-spectrum consensus. S.3822 is the legislation that answers all of them.